Icatibanto Stada (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor on blood vessels, it stops bradykinin‑induced vasodilation and increased permeability, thereby preventing the fluid leakage that causes the swelling characteristic of hereditary angioedema.

The dosage and administration schedule for Icatibanto Stada are determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of attacks, and individual response. The prescriber will provide specific instructions for each case.

Safety data for icatibant in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Icatibanto Stada is a bradykinin B2 receptor antagonist, whereas alternative therapies may include C1‑esterase inhibitor concentrates or newer monoclonal antibodies targeting kallikrein. Icatibant offers rapid subcutaneous administration and direct blockade of bradykinin, making it effective for acute attacks, while other options may focus on replacement or upstream inhibition.

The product must be stored at 2‑8 °C (refrigerated). Keep it in the original packaging, protect it from light, and avoid freezing or shaking the vial, as temperature stability is essential for maintaining potency.

Icatibanto Stada is supplied as a sterile solution for subcutaneous injection. The prescriber or a trained healthcare professional will administer the dose into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, unexpected angioedema unrelated to hereditary episodes, and significant hypotension. Patients should be observed after injection and instructed to seek immediate medical attention if they experience any signs of a severe reaction.

Patients with a known hypersensitivity to icatibant or any of its excipients should avoid the product. Additionally, individuals currently receiving ACE inhibitors or other bradykinin‑enhancing drugs should discuss alternative therapies with their physician due to increased risk of angioedema.